These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 24920586)

  • 41. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
    Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
    Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice.
    Fogli S; Galimberti S; Gori V; Del Re M; Danesi R
    Pharmacol Res; 2021 May; 167():105537. PubMed ID: 33684510
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma.
    Tang W; Li Y; Zhang L; Zhong X; Liang Q; Zheng Y; Liu Y; Wang Y; Wang X; Zeng Y; Fang B; Zheng L; Niu T
    Cancer Med; 2024 Jul; 13(14):e7435. PubMed ID: 39031941
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
    Mateos MV; Masszi T; Grzasko N; Hansson M; Sandhu I; Pour L; Viterbo L; Jackson SR; Stoppa AM; Gimsing P; Hamadani M; Borsaru G; Berg D; Lin J; Di Bacco A; van de Velde H; Richardson PG; Moreau P
    Haematologica; 2017 Oct; 102(10):1767-1775. PubMed ID: 28751562
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [
    Gupta N; Zhang S; Pusalkar S; Plesescu M; Chowdhury S; Hanley MJ; Wang B; Xia C; Zhang X; Venkatakrishnan K; Shepard DR
    Invest New Drugs; 2018 Jun; 36(3):407-415. PubMed ID: 28932928
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor.
    Gupta N; Hanley MJ; Diderichsen PM; Yang H; Ke A; Teng Z; Labotka R; Berg D; Patel C; Liu G; van de Velde H; Venkatakrishnan K
    Clin Pharmacol Ther; 2019 Feb; 105(2):376-387. PubMed ID: 29446068
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
    Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
    Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib.
    Kumar SK; LaPlant B; Roy V; Reeder CB; Lacy MQ; Gertz MA; Laumann K; Thompson MA; Witzig TE; Buadi FK; Rivera CE; Mikhael JR; Bergsagel PL; Kapoor P; Hwa L; Fonseca R; Stewart AK; Chanan-Khan A; Rajkumar SV; Dispenzieri A
    Blood Cancer J; 2015 Aug; 5(8):e338. PubMed ID: 26275080
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.
    Vogl DT; Martin TG; Vij R; Hari P; Mikhael JR; Siegel D; Wu KL; Delforge M; Gasparetto C
    Leuk Lymphoma; 2017 Aug; 58(8):1872-1879. PubMed ID: 28140719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma.
    Delimpasi S; Dimopoulos MA; Straub J; Symeonidis A; Pour L; Hájek R; Touzeau C; Bhanderi VK; Berdeja JG; Pavlíček P; Matous JV; Robak PJ; Suryanarayan K; Miller A; Villarreal M; Cherepanov D; Srimani JK; Yao H; Labotka R; Orlowski RZ
    Am J Hematol; 2024 Sep; 99(9):1746-1756. PubMed ID: 38856176
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
    Gupta N; Hanley MJ; Venkatakrishnan K; Wang B; Sharma S; Bessudo A; Hui AM; Nemunaitis J
    J Clin Pharmacol; 2016 Oct; 56(10):1288-95. PubMed ID: 26872892
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical Efficacy and Safety of Ixazomib-Containing Regimens in the Treatment of Patients with Multiple Myeloma].
    Chen R; Xue LG; Zhou H; Jia T; Cai ZM; Zhu YX; Miao L; Wei JF; Zhao LD; Mao JP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):483-492. PubMed ID: 38660856
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma.
    Dhakal B; D'Souza A; Hamadani M; Arce-Lara C; Schroeder K; Chhabra S; Shah NN; Gauger K; Keaton T; Pasquini M; Hari P
    Blood Cancer J; 2019 Jul; 9(8):56. PubMed ID: 31358733
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of Gastrointestinal Toxicities From Ixazomib: Tips to Curb Nausea, Vomiting, Diarrhea, and Constipation.
    Hall KH
    Oncology (Williston Park); 2019 Mar; 33(3):89-90. PubMed ID: 30866030
    [No Abstract]   [Full Text] [Related]  

  • 57. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
    Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
    Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
    Harrison SJ; Mainwaring P; Price T; Millward MJ; Padrik P; Underhill CR; Cannell PK; Reich SD; Trikha M; Spencer A
    Clin Cancer Res; 2016 Sep; 22(18):4559-66. PubMed ID: 27117181
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].
    Ri M
    Rinsho Ketsueki; 2018; 59(10):2162-2168. PubMed ID: 30305522
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral ixazomib maintenance therapy in multiple myeloma.
    Offidani M; Corvatta L; Gentili S; Maracci L; Leoni P
    Expert Rev Anticancer Ther; 2016; 16(1):21-32. PubMed ID: 26588946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.